A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

NCT00051597 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Hodgkin Disease
Lymphoma, Large-Cell
Sarcoma, Kaposi
Lymphoma, T-Cell, Cutaneous
Lymphoma, B-Cell

Interventions

DRUG: SGN-30 (monoclonal antibody)

Sponsor

Seagen Inc.